In Q4 2025, Genmab generated revenue of 1058000000 and net profit of 31000000, supported primarily by strong royalty income and product sales while continuing to invest in its late-stage pipeline.

For the three months ended September 30, 2025, Genmab generated $1022000000 in revenue and reported net income of $401000000. Diluted EPS was $6.46 and Earnings per ADS were $0.65.

Genmab delivered robust Q2 2025 results with 19% year-over-year revenue growth. The performance was fueled by strong royalty revenues from DARZALEX and Kesimpta, as well as increased net product sales of EPKINLY. Despite higher costs, operating profit and net income both rose significantly, reflecting effective commercialization strategies and pipeline expansion.

Genmab delivered solid Q4 2024 results with revenue reaching DKK 21,526 million, an increase of 31% year-over-year. Net profit surged to DKK 7,844 million, supported by strong DARZALEX and Kesimpta royalties. Operating profit improved to DKK 6,703 million, while cash and cash equivalents stood at DKK 9,858 million.